PCOS

Moneli Golara Consultant Obstetrician and Gynaecologist Barnet Hospital, Royal Free NHS Trust

INTRODUCTION

- Heterogeneous, complex genetic trait
- Aetiology is unclear
- Common cause of menstrual irregularity
- Common cause of subfertility
- Also a cause of hyperandrogenism
 - Acne
 - Hirsutism

First described by Stein and Leventhal in 1935

INTRODUCTION

Polycystic ovaries- does not mean Polycystic Ovarian Syndrome

● 4-12% of population

• Diagnosis: 2003 Rotterdam criteria

2 of the following 3 required

- Oligo or anovulation (menstrual irregularity)
- Hyperandrogenism
- USS appearance of Polycystic ovaries

DIAGNOSIS

Menstrual dysfunction

- Typically begins in pripubertal period
- Menarche may be delayed
- Normally oligomenorrhoea
 - Less than 9 periods a year
- Amenorrhoea
 - No periods for 3 or more consecutive months
- Anovulation
- Infertility

DIAGNOSIS

Androgen excess

- Clinical signs
- Acne
- Hirsutism
 - Excess thick pigmented body hair
 - Upper lip, chin, midsternum, lower abdomen
- Male pattern hair loss
- Less common virilisation
 - Clitoromegaly
 - Deepening of voice
 - More likely above due to androgen secreting tumour

DIAGNOSIS

Polycystic appearance of Ovaries

- Multiple follicles
- Thick stroma

However this may also be seen
In normal cycling women
Isolated finding is of no
clinical significance



CLINICAL MANIFESTATIONS

- 40-85% of women with PCOS are overweight
- Not a diagnostic criteria
- Insulin resistance is present
 - 30% of lean
 - 70% of overweight
- Increased risk of type 2 Diabetes
- Increased risk of CHD
- Sleep apneoa
- Metabolic syndrome
- Mood disorder- anxiety, depression, binge eating

Menstrual cycle





CLINICAL MANIFESTATION

- Ovulation leads to progesterone secretion and menstruation
- Chronic anovulation results in lack of progesterone and increased estrogen
- Obesity contributes to hyperestrogenic state
- Chronic stimulation of endometrium with lack of menstruation can lead to endometrial hyperplasia
- If untreated, this can lead to cancer

EVALUATION

• Clinical picture

- BMI measurement
- Glucose intolerance
- Dyslipidaemia
- Fatty liver
- Obstructive sleep apneoa

 Based on Rotterdam criteria, history and examination should be enough in most women

EVALUATION

• Hirsutism

- Beware ethnic variation
- East asian women least hairy
- White european and black women intermediate
- Middle eastern, south asian and mediterranean most hairy

• Diagnosis of exclusion

- Exclude other cases of amenorrhoea
- Menopause
- Pregnancy
- Thyroid disorder, hyperprolactinoma

OTHER CONDITIONS

Androgen excess

- Tumours
- Ovarian hyperthecosis
- Congenital adrenal hyperplasia

INVESTIGATIONS

• Biochemistry

- TFT
- Prolactin
- FSH- to rule out menopause
- LH/FSH ratio- can be helpful but not diagnostic criteria
- Must be >2 to 3:1
- Must be done in follicular phase but most women are oligomenorrhoeic
- Serum totalTestosterone levels if very raised may be due to other causes
- Possibly SHBG- if low then confirms diagnosis

INVESTIGATIONS

• Ultrasound

- Perfomed as part of diagnosis
- However not always needed
- Absence of Poly cystic morphology does not exclude
- Useful if only one either criteria present
- If scan is to be done then must be Transvaginal
- Remember these are follicles and not cysts
- 12 or more follicles witth large ovaries
- Unilateral PCO is sufficient
- Can also check for endometrial thickness

IGNORE INCIDENTAL FINDING



Management depends on goals

Goals are

- Amelioration of hyperandrogenic symptoms
- Metabolic disorders
 - o Obesity
 - Type 2 diabetes
 - Cardiovascular disease
- Prevention of Endometrial hyperplasia
 - Due to chronic anovulation and estrogen excess
- Contraception
- Ovulation induction

- Lifestyle changes
 - Diet and exercise for weight reduction inObeste women
 - Improves insulin resistance and hyperandrogenism
 - Fertility improves
 - Multidisciplinary management
 - Gynaecology
 - o Dietician
 - Endocrinologist
 - Clinical psychologist

Oral Contraceptive Pill

- Mainstay of treatment
- Treats hyperandrogenism
 - Increases SHBG which mops up excess testosterone
 - Yasmin- contains drospirenone or Dianette which has cyproterone acetate- anti androgenic
- Regulates Menses
- Endometrial protection
- Improve insulin sensitivity

However, not useful if goal is to peruse a pregnancy

Oral Contraceptive Pill- risks

- Increased risk of VTE particularly if obese
- Risk assessment important
 - BMI <30
 - o Age
 - Smoking status
 - Family history of VTE

• Can use Progesterone only pill

- Mini pill ie cerazette
- Or cyclical progestogen therapy to induce menstruation

Goals- endometrial protection

- Progestagen therapy ie Norethisterone of Provera cyclically
- Mirena IUCD

Goals- Hirsutism

- OCP
- Antiandrogens
 - Spironolactone
 - Cyproternone acetate
 - Finasterite
 - Flutamide- hepatotoxicity
 - Laser hair removal/ waxing
 - Vaniqa Topical antiandrogen that prevents hair growth but must be used indefinitely

Goals- Weight loss

- Lifestyle changes
 - Even 5-10% weight loss can result in ovulation
- No diet superior to other
- Low carb diets however very popular
- Bariatric surgery

Goals - Metabolic disorders

- Weight loss
- Metformin
- Statins

Goals- Anovulatory infertility

- Weight loss
- Ovulation induction
 - Clomiphene citrate from D2-D6 of cycle
 - Ensure semenalysis normal
 - o Letrozole
 - Metformin
 - Exogenous gonadotrophins (IVF/IUI)
- Laparoscopic Ovarian drilling
 - Too invasive but effective if all else fails

OVARIAN DRILLING





METFORMIN

- Inhibits production of hepatic glucose
- Increases fatty acid oxidation
- Enhances Insulin sensitivity
- Observational studies
 - Reducing serum androgens and menstrual cycle
 - Effective in achieving ovulation
- Randomised studies had conflicting results
 - No consensus on dose and duration in the latest Cochrane review



Body Weight

- May achieve weight loss
- Randomised control trials failed to confirm this
- Combined with lifestyle changes may work

• Ovulation Induction

 One study found higher live birth rates with Metformin- but only just reached statistical significance

RCOG SCIENTIFIC PAPER

- August 2017
- Conclusion

Metformin appears to have limited role in improving reproductive outcomes in PCOS but in patient specific groups- ie obesity or those with higher impaired glucose tolerance or type 2 diabetes'

CONCLUSION

- Common problem
- Long term sequelae
- Treatment depends on goal
- Mainstay is weight loss and lifestyle changes
- Remember psychological impact
- Avoid labelling